Organ support & nutrition

External validation of Sequential Organ Failure Assessment (SOFA) 2 score: a retrospective Chinese cohort study

Ann Intensive CarePublished Retrospective cohort study

Authors' conclusion

In this external validation, SOFA-2 demonstrated improved discrimination for ICU mortality and more consistent score distribution than SOFA-1.

Study context

Population
Adults admitted to intensive care units (ICUs) in China, 2014–2024; SOFA calculated from first 7 ICU days
Participants
118,542 adults
Exposure
SOFA-2 vs SOFA-1 score
Outcome
ICU mortality (discrimination by AUROC)
Methodological detailsmulticentre, external validation, Multiple approaches applied to address missing data
  • Multicentre
  • External validation
  • Multiple approaches applied to address missing data

Main finding

As reported in the abstract

Discrimination for ICU mortality
GroupValueAUROC
SOFA-280.9% (95% CI 80.3%–81.5%)80.9%
SOFA-176.7% (95% CI 76.0%–77.4%)76.7%

Value

SOFA-280.9% (95% CI 80.3%–81.5%)
SOFA-176.7% (95% CI 76.0%–77.4%)

AUROC

SOFA-280.9%
SOFA-176.7%

Observational data: associations, not effects.

Further findings

OutcomeOR (95% CI)
ICU mortality per 1-point increase in SOFA-21.33 (1.33–1.35)
OutcomeSOFA-2SOFA-1
Between-cohort varianceIndicating greater robustness across these cohorts0.070.23

ICU and hospital mortality (overall cohort)

Died in ICU
5,286 (4.45%)
Died during hospitalisation
6,173 (5.2%)

SOFA-2 trajectories over first 7 days

Widening divergence between survivors and non-survivors

SOFA-2 subscores and total scores

Higher SOFA-2 subscores (0-4) and total scores associated with lower frequency and higher ICU mortality

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

External validation of SOFA 2 score: a retrospective Chinese cohort study. Ann Intensive Care. Published 25 June 2026. doi:10.1016/j.aicoj.2026.100107

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.